A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

Conditions

• Hidradenitis Suppurativa

Eligibility Criteria

Sex

ALL

Age

12 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Sonelokimab — DRUG
  Sonelokimab

Study Details

This is a study to evaluate the long-term safety, tolerability, and efficacy of sonelokimab in participants with moderate to severe hidradenitis suppurativa who were previously enrolled in a parental study.

Key Dates

Start date

Jun 27, 2025

Status verified

Jun 2026

Primary completion

Jun 13, 2028

Completion

Jun 13, 2028

Study Design

Enrollment

835 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Experimental: sonelokimab
  All participants will receive sonelokimab 120 mg Q4W for up to 2 years

Primary Outcome Measure

Long-term safety and tolerability of sonelokimab: Adverse events (AEs) following treatment with sonelokimab [ Time Frame: 2.5-3 years ]

Locations (49)

Find similar trials in Birmingham, AL

Related Studies

• The Ohio State University Dermatology Biorepository
  Recruiting · Ohio State University · Columbus, Ohio
• Clinical and Biological Characteristics of Hidradenitis Suppurativa
  Recruiting · University of California, San Francisco · San Francisco, California
• Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository
  Recruiting · University of California, San Francisco · San Francisco, California
• Battlefield Acupuncture for Pain in Hidradenitis Suppurativa
  Recruiting · Wayne State University · Dearborn, Michigan